Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group.
Journal: 1997/September - Gut
ISSN: 0017-5749
PUBMED: 9274464
Abstract:
There is considerable confusion over the management of Helicobacter pylori infection, particularly among primary care physicians, and numerous European countries lack national guidelines in this rapidly growing area of medicine. The European Helicobacter Pylori Study Group therefore organised a meeting in Maastricht of H pylori experts, primary care physicians and representatives of National Societies of Gastroenterology from Europe to establish consensus guidelines on the management of H pylori at the primary care and specialist levels, and to consider general health care issues associated with the infection. As in previous guidelines, eradication therapy was recommended in all H pylori positive patients with peptic ulcer disease. Additionally, at the primary care level in dyspeptic patients < 45 years old and with no alarm symptoms, diagnosis is recommended by non-invasive means (13C urea breath test, serology) and if H pylori positive the patient should be treated. Moreover, at the specialist level the indications for eradication of H pylori were also broadened to include H pylori positive patients with functional dyspepsia in whom no other possible causes of symptoms are identified by the specialist (after a full investigation including endoscopy, ultrasound and other necessary investigations), patients with low grade gastric mucosa associated lymphoid tissue (MALT) lymphoma (managed in specialised centres) and those with gastritis with severe macro- or microscopic abnormalities. There was consensus that treatment regimens should be simple, well tolerated and achieve an eradication rate of over 80% on an intention to treat basis. It was strongly recommended, therefore, that eradication treatment should be with proton pump inhibitor based triple therapy for seven days, using a proton pump inhibitor and two of the following: clarithromycin, a nitroimidazole (metronidazole or tinidazole) and amoxycillin.
Relations:
Content
Citations
(143)
References
(30)
Diseases
(2)
Drugs
(9)
Chemicals
(1)
Organisms
(2)
Similar articles
Articles by the same authors
Discussion board
Gut 41(1): 8-13

Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group.

Abstract

There is considerable confusion over the management of Helicobacter pylori infection, particularly among primary care physicians, and numerous European countries lack national guidelines in this rapidly growing area of medicine. The European Helicobacter Pylori Study Group therefore organised a meeting in Maastricht of H pylori experts, primary care physicians and representatives of National Societies of Gastroenterology from Europe to establish consensus guidelines on the management of H pylori at the primary care and specialist levels, and to consider general health care issues associated with the infection. As in previous guidelines, eradication therapy was recommended in all H pylori positive patients with peptic ulcer disease. Additionally, at the primary care level in dyspeptic patients < 45 years old and with no alarm symptoms, diagnosis is recommended by non-invasive means (13C urea breath test, serology) and if H pylori positive the patient should be treated. Moreover, at the specialist level the indications for eradication of H pylori were also broadened to include H pylori positive patients with functional dyspepsia in whom no other possible causes of symptoms are identified by the specialist (after a full investigation including endoscopy, ultrasound and other necessary investigations), patients with low grade gastric mucosa associated lymphoid tissue (MALT) lymphoma (managed in specialised centres) and those with gastritis with severe macro- or microscopic abnormalities. There was consensus that treatment regimens should be simple, well tolerated and achieve an eradication rate of over 80% on an intention to treat basis. It was strongly recommended, therefore, that eradication treatment should be with proton pump inhibitor based triple therapy for seven days, using a proton pump inhibitor and two of the following: clarithromycin, a nitroimidazole (metronidazole or tinidazole) and amoxycillin.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.3M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Penston JG, Mistry KR. Eradication of Helicobacter pylori in general practice. Aliment Pharmacol Ther. 1996 Apr;10(2):139–145. [PubMed] [Google Scholar]
  • Bell GD, Powell KU, Burridge SM, Bowden AF, Atoyebi W, Bolton GH, Jones PH, Brown C. Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 1995 Feb;9(1):41–46. [PubMed] [Google Scholar]
  • Heikkinen M, Pikkarainen P, Takala J, Räsänen H, Julkunen R. Etiology of dyspepsia: four hundred unselected consecutive patients in general practice. Scand J Gastroenterol. 1995 Jun;30(6):519–523. [PubMed] [Google Scholar]
  • Feldman RA, Deeks JJ, Evans SJ. Multi-laboratory comparison of eight commercially available Helicobacter pylori serology kits. Helicobacter pylori Serology Study Group. Eur J Clin Microbiol Infect Dis. 1995 May;14(5):428–433. [PubMed] [Google Scholar]
  • Duodenal Ulcer Trials. Gut. 1995;37(Suppl 1):A85–A87.[PMC free article][Google Scholar]
  • Tham TC, McLaughlin N, Hughes DF, Ferguson M, Crosbie JJ, Madden M, Namnyak S, O'Connor FA. Possible role of Helicobacter pylori serology in reducing endoscopy workload. Postgrad Med J. 1994 Nov;70(829):809–812.[PMC free article] [PubMed] [Google Scholar]
  • Sobala GM, Crabtree JE, Pentith JA, Rathbone BJ, Shallcross TM, Wyatt JI, Dixon MF, Heatley RV, Axon AT. Screening dyspepsia by serology to Helicobacter pylori. Lancet. 1991 Jul 13;338(8759):94–96. [PubMed] [Google Scholar]
  • Patel P, Khulusi S, Mendall MA, Lloyd R, Jazrawi R, Maxwell JD, Northfield TC. Prospective screening of dyspeptic patients by Helicobacter pylori serology. Lancet. 1995 Nov 18;346(8986):1315–1318. [PubMed] [Google Scholar]
  • Sonnenberg A. Cost-benefit analysis of testing for Helicobacter pylori in dyspeptic subjects. Am J Gastroenterol. 1996 Sep;91(9):1773–1777. [PubMed] [Google Scholar]
  • Briggs AH, Sculpher MJ, Logan RP, Aldous J, Ramsay ME, Baron JH. Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age. BMJ. 1996 May 25;312(7042):1321–1325.[PMC free article] [PubMed] [Google Scholar]
  • Fendrick AM, Chernew ME, Hirth RA, Bloom BS. Alternative management strategies for patients with suspected peptic ulcer disease. Ann Intern Med. 1995 Aug 15;123(4):260–268. [PubMed] [Google Scholar]
  • Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996 Oct;20(10):1161–1181. [PubMed] [Google Scholar]
  • Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology. 1996 Apr;110(4):1244–1252. [PubMed] [Google Scholar]
  • Graham DY, Hepps KS, Ramirez FC, Lew GM, Saeed ZA. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol. 1993 Nov;28(11):939–942. [PubMed] [Google Scholar]
  • Labenz J, Börsch G. Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse. Digestion. 1994;55(1):19–23. [PubMed] [Google Scholar]
  • Rokkas T, Karameris A, Mavrogeorgis A, Rallis E, Giannikos N. Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease. Gastrointest Endosc. 1995 Jan;41(1):1–4. [PubMed] [Google Scholar]
  • Phull PS, Ryder SD, Halliday D, Price AB, Levi AJ, Jacyna MR. The economic and quality-of-life benefits of Helicobacter pylori eradication in chronic duodenal ulcer disease--a community-based study. Postgrad Med J. 1995 Jul;71(837):413–418.[PMC free article] [PubMed] [Google Scholar]
  • Kosunen TU, Seppälä K, Sarna S, Sipponen P. Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori. Lancet. 1992 Apr 11;339(8798):893–895. [PubMed] [Google Scholar]
  • Buckley M, O'Morain C. Helicobacter pylori eradication--a surrogate marker for duodenal ulcer healing. Eur J Gastroenterol Hepatol. 1996 May;8(5):415–416. [PubMed] [Google Scholar]
  • Miehlke S, Bayerdörffer E, Lehn N, Mannes GA, Höchter W, Weingart J, Sommer A, Heldwein W, Müller-Lissner S, Bästlein E, et al. Recurrence of duodenal ulcers during five years of follow-up after cure of Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 1995 Oct;7(10):975–978. [PubMed] [Google Scholar]
  • Labenz J, Tillenburg B, Peitz U, Börsch G. Long-term consequences of Helicobacter pylori eradication: clinical aspects. Scand J Gastroenterol Suppl. 1996;215:111–115. [PubMed] [Google Scholar]
  • Digestive Disease Week and the 96th annual meeting of the American Gastroenterological Association. San Francisco, California, May 19-22, 1996. Abstracts. Gastroenterology. 1996 Apr;110(4 Suppl):A1–1591. [PubMed] [Google Scholar]
  • Talley NJ. A critique of therapeutic trials in Helicobacter pylori-positive functional dyspepsia. Gastroenterology. 1994 May;106(5):1174–1183. [PubMed] [Google Scholar]
  • McCarthy C, Patchett S, Collins RM, Beattie S, Keane C, O'Morain C. Long-term prospective study of Helicobacter pylori in nonulcer dyspepsia. Dig Dis Sci. 1995 Jan;40(1):114–119. [PubMed] [Google Scholar]
  • Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Liedman B, Lamers CB, Jansen JB, Dalenback J, Snel P, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 1996 Apr 18;334(16):1018–1022. [PubMed] [Google Scholar]
  • Unge P. Review of Helicobacter pylori eradication regimens. Scand J Gastroenterol Suppl. 1996;215:74–81. [PubMed] [Google Scholar]
  • Bell GD, Powell KU, Burridge SM, Bowden AF, Atoyebi W, Bolton GH, Jones PH, Brown C. Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 1995 Feb;9(1):41–46. [PubMed] [Google Scholar]
  • Moayyedi P, Sahay P, Tompkins DS, Axon AT. Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimen to eradicate Helicobacter pylori. Eur J Gastroenterol Hepatol. 1995 Sep;7(9):835–840. [PubMed] [Google Scholar]
  • Labenz J, Stolte M, Rühl GH, Becker T, Tillenburg B, Sollböhmer M, Börsch G. One-week low-dose triple therapy for the eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 1995 Jan;7(1):9–11. [PubMed] [Google Scholar]
  • Jaup BH, Norrby A. Low dose, short-term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers. Am J Gastroenterol. 1995 Jun;90(6):943–945. [PubMed] [Google Scholar]
  • Lind T, Veldhuyzen van Zanten S, Unge P, Spiller R, Bayerdörffer E, O'Morain C, Bardhan KD, Bradette M, Chiba N, Wrangstadh M, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter. 1996 Sep;1(3):138–144. [PubMed] [Google Scholar]
  • Lind T, Veldhuyzen van Zanten S, Unge P, Spiller R, Bayerdörffer E, O'Morain C, Bardhan KD, Bradette M, Chiba N, Wrangstadh M, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter. 1996 Sep;1(3):138–144. [PubMed] [Google Scholar]
  • Digestive Disease Week and the 96th annual meeting of the American Gastroenterological Association. San Francisco, California, May 19-22, 1996. Abstracts. Gastroenterology. 1996 Apr;110(4 Suppl):A1–1591. [PubMed] [Google Scholar]
  • Labenz J, Peitz U, Tillenburg B, Becker T, Börsch G, Stolte M. Kurzzeit-Tripel-Therapie mit Pantoprazol, Clarithromycin und Metronidazol zur Eradikation von Helicobacter pylori. Leber Magen Darm. 1995 May;25(3):122–127. [PubMed] [Google Scholar]
Abstract
There is considerable confusion over the management of Helicobacter pylori infection, particularly among primary care physicians, and numerous European countries lack national guidelines in this rapidly growing area of medicine. The European Helicobacter Pylori Study Group therefore organised a meeting in Maastricht of H pylori experts, primary care physicians and representatives of National Societies of Gastroenterology from Europe to establish consensus guidelines on the management of H pylori at the primary care and specialist levels, and to consider general health care issues associated with the infection. As in previous guidelines, eradication therapy was recommended in all H pylori positive patients with peptic ulcer disease. Additionally, at the primary care level in dyspeptic patients < 45 years old and with no alarm symptoms, diagnosis is recommended by non-invasive means (13C urea breath test, serology) and if H pylori positive the patient should be treated. Moreover, at the specialist level the indications for eradication of H pylori were also broadened to include H pylori positive patients with functional dyspepsia in whom no other possible causes of symptoms are identified by the specialist (after a full investigation including endoscopy, ultrasound and other necessary investigations), patients with low grade gastric mucosa associated lymphoid tissue (MALT) lymphoma (managed in specialised centres) and those with gastritis with severe macro- or microscopic abnormalities. There was consensus that treatment regimens should be simple, well tolerated and achieve an eradication rate of over 80% on an intention to treat basis. It was strongly recommended, therefore, that eradication treatment should be with proton pump inhibitor based triple therapy for seven days, using a proton pump inhibitor and two of the following: clarithromycin, a nitroimidazole (metronidazole or tinidazole) and amoxycillin.
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.